Is lympro a $500 million opportunity in the US? In listening to Gerald's call today he mentioned lympro is actually a $150 million opportunity in the US which he said was confirmed by other BPs. If so, how did it shrink so much? Is the remaining $350 million expected from outside of the research realm? Gerald gave no clarification on this that I can recall hearing.

And why are people attacking me for bringing up obvious discrepancies created by the CEO? Why is it becoming taboo to actually make a legitimate observation when your CEO isn't making good on his own words? I thought we are shareholders and not slaves.